PMA device
IsoPSA Assay
Cleveland Diagnostics, Inc. · Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF, Class III) · First FDA decision Nov 28, 2025, newest Nov 28, 2025Prostate cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "IsoPSA"
MAUDE reports
0
Brand "IsoPSA", since 2015
PubMed studies
20
Mentioning "IsoPSA"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- IsoPSA AssayBreakthroughPMA
P200048 · Decided Nov 28, 2025 · 1,796 days after receipt
Device type: Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Codes That Are Not Covered by Medicare (Removal of ICD-9-CM Code V76.44, Prostate Cancer Screening, From the List)Coding analysisReview closedCAG-00297NUpdated Sep 14, 2026
- Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal CancerNational determinationOn the books210.2Updated Sep 30, 2025
- Prostate Cancer Screening TestsNational determinationOn the books210.1Updated Dec 11, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "IsoPSA", any status and sponsor, newest update first.
No registered device study names "IsoPSA".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "IsoPSA", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRF
371 reports: 371 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "IsoPSA"[tiab]. The summary above synthesizes these.
- IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
Scovell JM, Stovsky M, Partin A, et al. · Urology · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study.
Klein EA, Partin A, Lotan Y, et al. · Urol Oncol · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.
Robinson HS, Lee SS, Barocas DA, et al. · Prostate Cancer Prostatic Dis · 2025Review
- IsoPSA density improves risk stratification and biopsy decision-making for clinically significant prostate cancer.
Wang B, Benidir T, Dortche K, et al. · Urol Oncol · 2026
- Solvent Interaction Analysis: A New Lens for Protein Structure and Diagnostics.
Zaslavsky BY, Stovsky M, Uversky VN · Int J Mol Sci · 2026Review
- IsoPSA® Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ࣙ4 ng/ml: A Real-World Observational Clinical Utility Study.
Scovell JM, Hettel D, Abouassaly R, et al. · Urol Pract · 2022
- Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature.
Benidir T, Hofmann M, Lone Z, et al. · Urology · 2022
- Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA.
Benidir T, Lone Z, Wood A, et al. · Urology · 2023
- MP05-20 ISOPSA Substantially Reduces Unneeded Biopsies in a Real-World Office Setting. Erratum.
J Urol · 2022Published Erratum
- Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review.
Assani KD, Pierce JM, Galloway LA, et al. · Curr Opin Urol · 2025Systematic Review, Research Support, N.I.H., Extramural
- Editorial Comment on "Low Baseline IsoPSA Index is Associated With a Prolonged Low Risk of Clinically Significant Prostate Cancer Diagnosis in Men With an Elevated PSA".
Assani KD, Scarpato KR · Urology · 2025Comment, Editorial
- The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
Klein EA, Chait A, Hafron JM, et al. · Eur Urol · 2017Comparative Study, Multicenter Study
Other devices of this type
Also filed under product code QRF.
- 4Kscore TestOpko Health, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.